The phase 3 INTERLINK-1 trial evaluated monalizumab plus cetuximab vs. cetuximab alone in patients with recurrent or metastatic HNSCC who have previously been treated with platinum-based chemotherapy and PD-L1 inhibitors but failed to meet the endpoints (125). Here, CD274 is linked to head and neck squamous cell carcinoma.